Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IMGO

Imago BioSciences (IMGO) Stock Price, News & Analysis

Imago BioSciences logo

About Imago BioSciences Stock (NASDAQ:IMGO)

Advanced Chart

Key Stats

Today's Range
$36.01
$36.01
50-Day Range
$35.78
$36.01
52-Week Range
$11.56
$36.09
Volume
N/A
Average Volume
171,367 shs
Market Capitalization
$1.22 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Receive IMGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Imago BioSciences and its competitors with MarketBeat's FREE daily newsletter.

IMGO Stock News Headlines

Trump’s Bitcoin Reserve is No Accident…
For the first time in history, we have a president who understands crypto's potential to bypass the banking system entirely. And Wall Street's biggest players know it. I've created a blueprint revealing how everyday investors can turn this historic shift into potentially life-changing wealth. Like the 75,000 new millionaires created in the last bull run— only this time with institutional backing.
Merck: Better Times Ahead On Approvals And Outlook
Clarus Lifesciences III, L.P.'s Net Worth
Anixa Biosciences Inc ANIX
See More Headlines

IMGO Stock Analysis - Frequently Asked Questions

Imago BioSciences, Inc. (NASDAQ:IMGO) posted its earnings results on Wednesday, November, 10th. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by $0.10.

Imago BioSciences (IMGO) raised $105 million in an initial public offering (IPO) on Friday, July 16th 2021. The company issued 7,000,000 shares at $14.00-$16.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that Imago BioSciences investors own include Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Advanced Micro Devices (AMD) and Alphabet (GOOG).

Company Calendar

Last Earnings
11/10/2021
Today
5/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMGO
Fax
N/A
Employees
27
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-42,310,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$6.40 per share
Price / Book
5.63

Miscellaneous

Free Float
28,783,000
Market Cap
$1.22 billion
Optionable
Not Optionable
Beta
2.82
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:IMGO) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners